AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The monopoly is about to end. By Rebecca Robbins In 2016, a blockbuster drug called Humira was poised to become a lot less valuable. The key patent on the...
Two lawsuits filed in Massachusetts and Germany claim the Pfizer-BioNTech Covid-19 vaccine violated Moderna’s mRNA patents. By Rebecca Robbins and Jenny Gross The vaccine manufacturer Moderna sued Pfizer and BioNTech on Friday, claiming that its rivals’ Covid-19 shot...
Rates are stalling in most low-income countries well short of the W.H.O.’s goal to immunize 70 percent of people in every nation. Some public health experts believe the momentum is gone forever. By Rebecca Robbins and Stephanie Nolen In the middle of last year, the...
The first-of-its-kind treatment, Paxlovid, has been found to be highly protective against severe illness. It could be available within a few days. By Rebecca Robbins and Carl Zimmer The Food and Drug Administration on Wednesday authorized the first pill for Covid-19,...
By Rebecca Robbins The pharmaceutical company Merck said on Friday that in a final analysis of a clinical trial, its antiviral pill reduced the risk of hospitalization and death among high-risk Covid patients by 30 percent, down from an earlier estimate of 50 percent....
Some poorer countries are paying more and waiting longer for the company’s vaccine than the wealthy — if they have access at all. By Rebecca Robbins Moderna, whose coronavirus vaccine appears to be the world’s best defense against Covid-19, has been...